Engineered Probiotics for Epithelial Barrier Restoration
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current therapies for inflammatory bowel diseases (IBD) primarily focus on suppressing inflammation, neglecting the importance of restoring epithelial barrier function, which is crucial for disease management.
Innovation Solution
Development of recombinantly engineered probiotic bacteria that secrete anti-inflammatory compounds, specifically muropeptide precursors, to enhance epithelial barrier integrity and reduce inflammation.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Object-affected harmful factors
If current anti-inflammatory therapies are used to treat IBD, then inflammation is suppressed, but epithelial barrier function is not restored
Solution Approach 1:
The patent introduces probiotic bacteria as an intermediary organism that performs dual functions: suppressing inflammation through immunomodulation and restoring epithelial barrier function through secretion of barrier-supporting compounds. This mediator bridges the gap between anti-inflammatory therapy and barrier repair that cannot be achieved by conventional drugs alone.
Solution Approach 2:
The probiotic bacteria serve multiple therapeutic functions simultaneously: (1) suppressing inflammatory responses, (2) restoring epithelial barrier integrity, and (3) preventing bacterial translocation. This multi-functional approach resolves the contradiction by addressing both inflammation suppression and barrier restoration through a single therapeutic agent.
2Reliability
If probiotic bacteria are engineered to secrete therapeutic compounds, then therapeutic efficacy is improved, but device complexity increases
Solution Approach 1:
The probiotic bacteria are engineered with self-regulating secretion systems that activate compound production in response to inflammatory signals or environmental cues within the gut. This self-service mechanism reduces the need for complex external control systems while maintaining high therapeutic efficacy through context-dependent compound secretion.
Solution Approach 2:
The patent utilizes changes in bacterial physiological parameters (such as gene expression levels, secretion rates, and metabolic states) in response to gut environment conditions to regulate therapeutic compound production. This parameter-based control achieves high efficacy without requiring complex engineering structures.
Data Source
AI summary
The present disclosure relates to novel pharmaceutical compositions comprising recombinantly engineered probiotic bacteria that can be used, inter alia, in the treatment of gastrointestinal inflammatory diseases and epithelial barrier function disorders. The probiotic bacteria preferably contain a nucleic acid encoding the heterodimeric protein of SEQ ID NO:1 and 2, or homologous sequences thereof sharing at least 80% identity with said sequences. In some embodiments, the pharmaceutical compositions described herein have particular application in the treatment or prevention of disease states associated with abnormally permeable epithelial barriers as well as inflammatory bowel diseases or disorders.